Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1
Open Access
- 1 January 2004
- journal article
- Published by American Society of Hematology in Blood
- Vol. 103 (1) , 85-92
- https://doi.org/10.1182/blood-2003-05-1446
Abstract
Adeno-associated viral (AAV) vectors (serotype 2) efficiently transduce skeletal muscle, and have been used as gene delivery vehicles for hemophilia B and for muscular dystrophies in experimental animals and humans. Recent reports suggest that AAV vectors based on serotypes 1, 5, and 7 transduce murine skeletal muscle much more efficiently than AAV-2, with reported increases in expression ranging from 2-fold to 1000-fold. We sought to determine whether this increased efficacy could be observed in species other than mice. In immunodeficient mice we saw 10- to 20-fold higher levels of human factor IX (hF.IX) expression at a range of doses, and in hemophilic dogs we observed approximately 50-fold higher levels of expression. The increase in transgene expression was due partly to higher gene copy number and a larger number of cells transduced at each injection site. In all immunocompetent animals injected with AAV-1, inhibitory antibodies to F.IX developed, but in immunocompetent mice treated with high doses of vector, inhibitory antibodies eventually disappeared. These studies emphasize that the increased efficacy of AAV-1 vectors carries a risk of inhibitor formation, and that further studies will be required to define doses and treatment regimens that result in tolerance rather than immunity to F.IX.Keywords
This publication has 23 references indexed in Scilit:
- Influence of Vector Dose on Factor IX-Specific T and B Cell Responses in Muscle-Directed Gene TherapyHuman Gene Therapy, 2002
- Risk and Prevention of Anti-factor IX Formation in AAV-Mediated Gene Transfer in the Context of a Large Deletion of F9Molecular Therapy, 2001
- Muscle-Directed Gene Transfer and Transient Immune Suppression Result in Sustained Partial Correction of Canine Hemophilia B Caused by a Null MutationMolecular Therapy, 2001
- Enhancement of Muscle Gene Delivery with Pseudotyped Adeno-Associated Virus Type 5 Correlates with Myoblast DifferentiationJournal of Virology, 2001
- Localization dose and time of antigens determine immune reactivitySeminars in Immunology, 2000
- Role of Vector in Activation of T Cell Subsets in Immune Responses against the Secreted Transgene Product Factor IXMolecular Therapy, 2000
- Clinical Protocol: Phase I Clinical Trial Utilizing Gene Therapy for Limb Girdle Muscular Dystrophy: alpha-, beta-, gamma-, or delta-Sarcoglycan Gene Delivered with Intramuscular Instillations of Adeno-Associated VectorsHuman Gene Therapy, 2000
- Use of a Liver-Specific Promoter Reduces Immune Response to the Transgene in Adenoviral VectorsHuman Gene Therapy, 1999
- Adeno-associated virus vectors can be efficiently produced without helper virusGene Therapy, 1998
- A Phase I/II Study of tgAAV-CF for the Treatment of Chronic Sinusitis in Patients with Cystic Fibrosis. Stanford University, Stanford, CaliforniaHuman Gene Therapy, 1998